Inactive Instrument

Precipio Inc Share Price Nasdaq

Equities

US74019L1070

Advanced Medical Equipment & Technology

Sales 2022 9.41M 786M Sales 2023 15.2M 1.27B Capitalization 9.23M 771M
Net income 2022 -12M -1B Net income 2023 -5M -418M EV / Sales 2022 1.12 x
Net cash position 2022 2.05M 171M Net cash position 2023 386K 32.24M EV / Sales 2023 0.58 x
P/E ratio 2022
-1.03 x
P/E ratio 2023
-1.44 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 93.88%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Precipio Inc

Managers TitleAgeSince
Chief Executive Officer 52 28/17/28
Director of Finance/CFO 57 01/17/01
Chief Tech/Sci/R&D Officer 40 -
Members of the board TitleAgeSince
Director/Board Member 64 01/21/01
Director/Board Member 62 09/18/09
Chairman 81 03/19/03
More insiders
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
More about the company